Human Papillomavirus Vaccination and Premature Ovarian Failure: A Disproportionality Analysis Using the Vaccine Adverse Event Reporting System by TATANG, Collins et al.
Vol.:(0123456789)
Drugs - Real World Outcomes 
https://doi.org/10.1007/s40801-021-00271-6
ORIGINAL RESEARCH ARTICLE
Human Papillomavirus Vaccination and Premature Ovarian Failure: 
A Disproportionality Analysis Using the Vaccine Adverse Event 
Reporting System
Collins Tatang1 · Teigna Arredondo Bisonó2 · Aurore Bergamasco2 · Francesco Salvo3,4 · Sue Ann Costa Clemens5 · 
Yola Moride2,6,7 
Accepted: 22 June 2021 
© The Author(s) 2021
Abstract
Introduction There have been public health concerns about a potential association between human papillomavirus (HPV) 
vaccines and premature ovarian failure (POF) in young women.
Objective To identify a potential safety signal of POF after HPV vaccination using the United States (US) Vaccine Adverse 
Event Reporting System (VAERS) database.
Methods We manually selected relevant MedDRA preferred terms related to POF and identified in VAERS all POF reports 
in women less than 40 years of age between 2 July 1990 and 14 May 2018, followed by a review of narratives to confirm 
the cases. We conducted descriptive analyses on age, POF type, HPV vaccine type (HPV2, HPV4, HPV9), time to onset of 
POF, and dose rank. We described trends in reporting over time and assessed a potential safety signal using the proportional 
reporting ratio (PRR).
Results Of the 228,341 eligible POF reports, 281 (0.1%) were suspected to be associated with HPV vaccines. Median patient 
age was 15 years (range 11–39 years). POF events consisted mainly of amenorrhea (80.4%) and premature menopause 
(15.3%). Mean number of reported POF events significantly increased after the first HPV vaccine launch in 2006 with 22.2 
POF cases/year up from 1.4 POF cases/year before the launch. PRR was 46.1 (95% confidence interval: 31.7–67.2) and 
sensitivity analyses yielded similar estimates.
Conclusion Our study suggests the presence of a potential safety signal of POF associated with HPV vaccination, which 
may only be partly attributed to notoriety bias. Due to the well-known limitations of spontaneous reporting data, further 
investigations are warranted.
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Key Points 
Using a quantitative approach, this study uncovered a 
potential safety signal of POF following HPV vaccina-
tion.
The large proportional reporting ratio (PRR) estimate 
obtained may not be entirely explained by reporting or 
notoriety bias, nor by the Weber effect.
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1 Introduction
Premature ovarian failure (POF) is the cessation of ovar-
ian function before 40 years of age, with a possibility of 
ovarian function fluctuating (a state called primary ovarian 
insufficiency [POI]) before complete cessation [1]. The 
time between onset of altered menstrual cycle as an initial 
symptom and POF diagnosis is variable and may reach 5 
years [2]. For young women POF has an important social 
and psychological impact, in addition to physiological con-
sequences such as loss of bone mineral density amongst 
others [3]. POF is a rare condition with an estimated prev-
alence of 0.87 per 1,000,000 person-months (95% confi-
dence interval (CI): 0.12–6.16) in 11- to 14-year-olds, and 
4.08 per 1,000,000 person-months (95% CI: 1.70–9.79) in 
15- to 18-year-olds [4]. About 74–90% of POF cases have 
an unknown etiology [1].
Concerns raised by the observations of cases of female 
infertility after human papillomavirus (HPV) vaccination 
emerged following the publication of two case series, respec-
tively in 2013 and 2014, involving POF in 14- to 21-year-
olds [1, 5]. Subsequently, safety statements on the absence 
of risk of infertility after HPV vaccination were made by the 
World Health Organization (WHO) Global Advisory Com-
mittee on Vaccine Safety (GACVS) as well as by the Centers 
for Disease Control and Prevention (CDC) and the US Food 
and Drug Administration (FDA) [6, 7]. In addition, a review 
of the POF cases reported to the United States (US) Vac-
cine Adverse Event Reporting System (VAERS) database 
was conducted. In this study there were 17 cases of POF 
identified, of which 15 were excluded because of insufficient 
information to confirm the diagnosis [8]. An observational 
study based on electronic health records (Vaccine Safety 
Datalink Study [VSD]) found no increased risk of POF after 
HPV vaccine, but was statistically underpowered [4]. Evi-
dence of an association was also not supported in a recent 
cross-sectional study conducted using US NHANES data, 
which was, however, based on inaccurate measurement of 
POF and self-reported past HPV vaccination [9].
During the time period covered by our study, there 
were three HPV vaccine types on the US market: bivalent 
(HPV2), quadrivalent (HPV4), and nonavalent (HPV9). 
Our study used a pharmacovigilance approach to identify 
a potential safety signal of POF associated with HPV vac-
cination in VAERS by: (i) identifying reported cases of POF 
events suspected to be associated with HPV vaccination with 
no exclusion on the basis of missing data; (ii) describing the 
characteristics of POF cases and trends over time in event 
types, HPV vaccine type, time to onset of POF from HPV 
vaccination, dose rank, and age group; and (iii) determin-
ing whether there is a potential safety signal of POF related 
to HPV vaccination through a disproportionality analysis.
2  Methods
2.1  Data Source
We used the VAERS, created in 1990 in the US to fulfil a 
requirement of the National Childhood Vaccine Injury Act 
of 1986, which consists of a spontaneous and voluntary 
reporting system for any suspected adverse drug reaction 
(ADR) associated with vaccine use [10]. The system can 
receive reports of suspected ADRs from healthcare pro-
fessionals, manufacturers, patients, parents, and caregiv-
ers [11]. The reporting form includes fields that capture 
information on the person who experienced the suspected 
ADR, the reporter, the suspected ADR, and the vaccine. 
Reports are coded using the Preferred Terms (PTs) of the 
Medical Dictionary for Regulatory Activities (MedDRA) 
[12]. Data from primary reports, after the removal of 
patient sensitive information, are publicly available on the 
VAERS website and through the CDC Wide Online Data 
for Epidemiologic Research (WONDER) tool. This data-
base receives reports from both US and non-US sources; 
between 2011 and 2014, VAERS received an annual aver-
age of 30,000 US reports and 6,000 non-US reports, with 
the majority (> 99%) from vaccine manufacturers [10].
2.2  Eligibility Criteria
Relevant PTs for POF events were manually identified a pri-
ori by two medical doctors with respective expertise in vac-
cinology (CT) and pharmacovigilance (GC) using Standard-
ized MedDRA Queries (SMQs) and examination of all PTs 
for either a symptom or a sign of POF. Events were divided 
into four categories: proportion of POF reports among HPV 
vaccine-associated reports, proportion of non-POF events in 
HPV vaccines, proportion of POF in other vaccines, and pro-
portion of non-POF events in other vaccines. The denomina-
tor for proportions was restricted to women below 40 years 
of age or of unknown age between 2 July 1990 (i.e., the date 
an adverse event was first reported in VAERS) and 14 May 
2018 (i.e., the date of data extraction). We defined expo-
sure to HPV vaccination by the mention, in a case report, of 
an exposure of at least one dose of any HPV vaccine type 
(bivalent, quadrivalent, or nonavalent) for which the ADR 
was suspected to have occurred. Regardless of the vaccine 
reported, we excluded reports of cases aged ≥ 40 years, of 
unknown sex (analyzed only in a sensitivity analysis), and 
with known causes of POF with their corresponding Med-
DRA codes (vaginal septum [10064513], idiopathic hypog-
onadotropic hypogonadism [10059594], Turner’s syndrome 
[10045181], pregnancy [10036556], and polycystic ovaries 
[10036049]).
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2.3  Study Outcomes
We assessed the following types of POF, with correspond-
ing MedDRA codes: amenorrhea (10001928), oligomenor-
rhea (10030295), premature menopause (10036601), ovar-
ian failure (10033165), blood follicle-stimulating hormone 
increased (10005534), blood follicle-stimulating hormone 
abnormal (10005532), estradiol decreased (10030229), and 
estradiol abnormal (10063266). In addition, the narrative of 
each case was reviewed to confirm that the amenorrhea was 
not due to pregnancy.
2.4  Data Analysis
We used frequencies and percentages to describe reports of 
POF associated with HPV vaccination, according to patient 
age, time between vaccination and onset of POF event, POF 
event type, HPV vaccine type (HPV2, HPV4, HPV9), dose 
rank, time period, and region (whether US or non-US). An 
analysis of all POF events (regardless of the suspected vac-
cine) was also undertaken in order to compare the annual 
number of POF case reports in the period before the launch 
of the first HPV vaccine (1990–2006) to the annual num-
ber post-launch (2006–2018) and used Fisher’s exact test to 
assess the statistical significance of the differences.
Disproportionality was evaluated using the proportional 
reporting ratio (PRR), which is the ratio of the proportion of 
reports of POF events suspected to be associated with HPV 
vaccination to the proportion of reports of POF events sus-
pected to be associated with all other vaccination in women 
age < 40 years or unknown age only [13]. The criteria for 
a signal of disproportionality were set at a PRR ≥ 2, the 
lower bound of the 95% CI for the PRR ≥ 1, and the number 
of cases ≥ 3 [14]. We conducted the following sensitivity 
analyses on the PRR: (i) inclusion of reports of unknown 
sex below 40 years of age; (ii) stricter definition of POF 
event (restricted to amenorrhea, premature menopause, and 
ovarian failure); (iii) exclusion of cases of unknown age; and 
(iv) restriction of the time period to post-launch only (July 
2006–14 May 2018).
3  Results
3.1  Reports of Premature Ovarian Dysfunction 
in Vaccine Adverse Event Reporting System 
(VAERS)
Figure 1 shows the flow of selection of reports, includ-
ing reasons for exclusion. There were 228,341 AE reports 
for females less than 40 years of age or of unknown age 
recorded in the VAERS database between 2 July 1990 and 
14 May 2018. Of those, 311 (0.14%) were POF events. 
Among the 311 POF cases, 281 (90.4%) were exposed to 
HPV vaccination (hence, were recorded in VAERS follow-
ing the launches of the vaccine starting in 2006) and 30 
(9.6%) were exposed to another vaccine. Of those 30, 23 
(76.7%) occurred prior to 2006 and seven (23.3%) occurred 
thereafter. Meanwhile, of the 228,030 cases of other AEs, 
78,220 (34.3%) were reported prior to 2006 and 149,810 
(65.7%) were reported thereafter, of which 38,276 (25.6%) 
were exposed to HPV vaccination while 111,534 (74.5%) 
were exposed to another vaccine.
3.2  Characteristics of Cases of Premature Ovarian 
Failure (POF) Suspected of Being Associated 
with Human Papillomavirus (HPV) Vaccination 
or Other Vaccination
The characteristics of the 281 POF events following HPV vac-
cination are described in Table 1. The median age of patients 
was 15 years at the time of reporting (range: 11–39 years). 
Over half of the cases (58.0%) were in the younger age group 
(< 20 years) and age was unknown for a large portion (27.0%). 
Time to onset of POF events after the date of HPV vaccine 
exposure was documented in 128 (45.6%) of cases; median 
was 20.5 days and ranged from 0 to 2,017 days (0–5.5 years). 
The great majority of cases (84.3%) had received the quad-
rivalent vaccine (HPV4), which was the first introduced on 
the US market in 2006. There were eight types of POF events, 
which were not mutually exclusive and fell into either clini-
cal or laboratory notifications: amenorrhea accounted for the 
majority of cases (80.4%), followed by premature menopause 
(15.3%). In addition, laboratory findings were available for 
only a minority of cases; 5.0% of cases for blood follicle-stim-
ulating hormone increased, 1.4% cases for estradiol decreased, 
and, 0.4% cases each for blood follicle-stimulating hormone 
abnormal and estradiol abnormal.
In relation to POF reports suspected to be associated 
with other vaccines between 1990 and 2018, there were 
30 reports, out of which 23 (76.7%) had data for age with 
a median of 25 years (range: 12–38 years). There were 
21 (70.0%) reports with data on duration from exposure 
to other vaccines to POF onset with a median of 11 days 
(range: 0–1951 days). Only four POF event types were 
recorded, with the majority being amenorrhea in about 
83.3% (25/30) of cases, while the rest were premature 
menopause (3.3%, one report), oligomenorrhoea (10.0%, 
three reports), and decreased estradiol level (3.3%, one 
report). There were about 17 other vaccines suspected to 
be linked to these 30 POF reports, which were: measles 
vaccine (one report), hepatitis B vaccine (nine reports), 
measles, mumps, and rubella vaccine (four reports), vari-
cella virus live vaccine (four reports), tetanus and diph-
theria toxoids vaccine (one report), tetanus toxoid (one 
report), Lyme disease vaccine (one report), rabies virus 
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vaccine (one report), hepatitis A vaccine (one report), 
anthrax vaccine (three reports), trivalent influenza virus 
vaccine (two reports), quadrivalent influenza virus vac-
cine (one report), inactivated polio vaccine (one report), 
meningococcal group B vaccine (one report), tetanus 
toxoid, reduced diphtheria toxoid, and acellular pertussis 
vaccine (one report), meningococcal conjugate vaccine 
(A,C,W-135,Y) (one report), and tick-borne encephalitis 
vaccine (one report).
3.3  POF Cases Before and After the Introduction 
of HPV Vaccines on the Market
Out of the 311 reports of POF events, 288 (92.6%) were 
reported in the time period after the first introduction of the 
HPV vaccine (i.e., 2006), while 23 (7.4%) were reported 
before its introduction (Table 2). As shown in Table 3, 
out of 288 reports of POF events in 2006–2018, the great 
majority (97.6%) were suspected to be associated with HPV 
aSome cases were counted for more than one reason of exclusion 
POF: Premature ovarian failure 
AE: Adverse event 
HPV: Human papilloma virus 
US and non-US cases of safety reports of AEs  
02 July 1990 - 14 May 2018  
(n=655,834) 
Excluded cases of safety reports of AEs 
(n=427,493) 




Male sex (n=218,524) 
- 
Idiopathic hypogonadotropic hypogonadism 
[n=1], Turner's syndrome [n=2], Pregnancy 
[n=7,055], Polycystic ovaries [n=47]) 
Included cases of safety reports of AEs for females,  
40 years, or unknown age 
(n=228,341) 
Cases of POF  
(n=311) 
Other AEs  
(n=228,030) 
Exposed to HPV vaccination  
(n=281) 
Exposed to HPV vaccination 
(n=38,276) 
Exposed to other vaccinations  
(n=30) 
Exposed to other vaccinations 
(n=189,754) 
age <
 Unknown sex (n=80,133) 
Age ≥ 40 years (n=173,444)
 Known causes of POF:
Fig. 1  Flow diagram of identification of eligible reports for the study. POF premature ovarian failure, AE adverse event, HPV human papilloma 
virus. aSome cases were counted for more than one reason of exclusion
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vaccination, while only seven (2.4%) were suspected to be 
associated with other vaccines. There was a statistically sig-
nificant shift in age distribution after the introduction of HPV 
vaccines: In the period after the introduction of HPV vaccine 
on the US market (2006–2018), more than half (57.3%) of the 
288 POF cases were of the younger age group (< 20 years) 
and age was unknown for a large portion (27.1%), while in 
Table 1   Summary of 
characteristics of POF cases 
following HPV vaccination  
(2 July 2006–14 May 2018)
HPV human papillomavirus, POF premature ovarian failure, HPV2 bivalent HPV vaccine, HPV4 quadriva-

















Premature menopause 43 15.3%
Ovarian failure 18 6.4%
Blood follicle-stimulating hormone increased 14 5.0%
Blood follicle-stimulating hormone abnormal 1 0.4%
Estradiol decreased 4 1.4%
Estradiol abnormal 1 0.4%
HPV vaccine types (year of market launch in the US)
HPV2 (2009) 22 7.8%
HPV4 (2006) 237 84.3%
HPV9 (2014) 9 3.2%
HPV type unknown 13 4.6%
Table 2  Distribution of POF cases before and after HPV vaccine 
introduction on the US market (N = 311)a
Fisher’s exact test: α = 0.05, P-value (two-tailed) = 5.434E-05
a Cases of POF, regardless of vaccine exposure
POF premature ovarian failure, HPV human papillomavirus
1990–2006 2006–2018
N % N %
Age (years)
 < 20 6 26.1 165 57.3
 20–29 8 34.8 41 14.2
 30–39 4 17.4 4 1.4
 Unknown 5 21.7 78 27.1
 Total 23 100 288 100
Table 3  Distribution of POF cases exposed to HPV vaccines and to 
other vaccines stratified by age group (2006–2018) (N = 288)a
Fisher’s exact test: α = 0.05, P-value (two-tailed) = 0.03523
POF premature ovarian failure, HPV human papillomavirus
a Cases of POF suspected to be due to vaccine exposure following 
market launch of first HPV vaccine in 2006
HPV vaccination Other vaccines
N % N %
Age (years)
 < 20 163 58.0 2 28.6
 20–29 39 13.9 2 28.6
 30–39 3 1.1 1 14.3
 Unknown 76 27.0 2 28.6
 Total 281 100 7 100
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the period before the introduction, about one-quarter (26.1%) 
of the 23 cases found were aged less than 20 years.
The age distribution of POF associated with HPV 
vaccines versus other vaccines was heterogeneous (p = 
0.03523); the majority of women with HPV vaccine-asso-
ciated POF were less than 20 years of age (58.0%), while 
there was no clustering in specific age groups for the other 
vaccines (Table 3).
As shown in Table 4, the distribution of POF reports by 
age group was homogenous across vaccine types (HPV2, 
HPV4, HPV9) (p = 0.3081), while the distribution of dose 
rank by vaccine type was heterogeneous (p = 0.03723). Het-
erogeneity of the latter was due to differences in the propor-
tion of reports with unknown dose rank. Overall, before the 
introduction of the HPV vaccine, the mean number of POF 
reports was 1.4 cases per year (accounting for 23 cases for 
other marketed vaccines), and following the introduction, it 
increased to 22.2 cases per year (accounting for 288 cases for 
both HPV vaccine and other vaccines) (p < 0.0001). After 
the introduction of the HPV vaccines, 21.6 cases suspected 
of being associated with HPV vaccine per year were reported, 
while 0.5 cases suspected of being associated with other vac-
cines per year were reported. As shown in Fig. 2, the number 
of POF reports suspected to be associated with HPV vac-
cination (n = 281) following the market launch of the HPV 
vaccine in 2006 has been increasing over time, with a peak 
occurring in July 2016.
3.4  Proportional Reporting Ratio
The distribution of adverse events (AEs) according to type 
(POF vs. other AEs) and vaccination status (HPV vaccines 
vs. other vaccines) is reported in Table 5. Using these counts 
the PRR was estimated at 46.1 (95% CI: 31.7–67.2).
An arbitrary time window of a 1-year interval was used 
and any POF event occurring within 30 days after HPV or 
other vaccination was not suspected to be associated with 
the vaccine. For HPV vaccination, a cluster distribution for 
the 45.6% (128/281) HPV vaccine-related POF reports with 
data on time to onset was observed. The reporting period 
31 days to 1 year from HPV vaccination was registered in 
32.0% (41/128) of POF cases (Fig. 3). On the other hand, 
the cluster distribution of POF cases suspected to be associ-
ated with other vaccines, of which 70.0% (21/30) reported 
data on time to onset, involved (28.6% [6/21]) reports that 
fell within 31 days to 1 year. It is not known if time to onset 
is from the first, second, or third dose of the vaccine. The 
risk window of 31 days to 1 year was also applied to other 
vaccine proportions.
3.5  Sensitivity Analysis on the Proportional 
Reporting Ratio
The first sensitivity analysis included the 80,133 cases 
(14 POF events and 80,119 other AEs) of unknown sex 
and age below 40 years. Assuming that these cases might 
have been women (conservative approach), the sensi-
tivity analysis yielded a PRR estimate of 52.6 (95% CI: 
36.2–76.6). When cases of POF events were restricted to 
amenorrhea, premature menopause and ovarian failure, 
the reports decreased by only 6.4% (PRR 50.2; 95% CI: 
33.6–75.0). The third sensitivity analysis involving the 
exclusion of reports of unknown age yielded a PRR esti-
mate of 47.4 (95% CI: 30.9–72.9). In the final sensitiv-
ity analysis, the time period was restricted to the period 
following market launch of the first HPV vaccine (i.e., 
July 2006 to 14 May 2018), and the PRR estimate was 
Table 4  Distribution of POF 
cases among HPV vaccine type 
stratified by age and dose rank 
(2006–2018)a
POF premature ovarian failure, HPV human papillomavirus
*p value, α = 0.05 = 0.3081
**p value, α = 0.05 = 0.03723
a Cases of POF, suspected to be associated with HPV vaccination





< 20 14 (63.6%) 136 (57.4%) 5 (55.6%) 8 (61.5%)
20–29 1 (4.5%) 38 (16.0%) – –
30–39 1 (4.5%) 2 (0.8%) – –
Unknown 6 (27.3%) 61 (25.7%) 4 (44.4%) 5 (38.5%)
Dose rank** Dose 1 9 (40.9%) 94 (39.7%) 5 (55.6%) 1 (7.7%)
Dose 2 3 (13.6%) 31 (13.1%) – 1 (7.7%)
Dose 3 6 (27.3%) 51 (21.5%) 1(11.1%) 1 (7.7%)
Unknown 4 (18.2%) 61(25.7%) 3 (33.3%) 10 (76.9%)
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more than double its initial estimate at 112.6 (95% CI: 
53.4–238.3). The observed peak in reporting that occurred 
in 2016 may be the result of notoriety bias. An additional 
sensitivity analysis was thus conducted excluding the 47 
cases reported in 2016, and the PRR remained high at 38.4 
(95% CI: 26.3–56.2).
4  Discussion
Using the US VAERS data, a high disproportionality in 
the reports was found, which suggests the presence of a 
potential signal of an association between HPV vaccine and 
POF events. To address some of the limitations of spon-
taneous data, such as missing data in the reports, namely 
unknown sex or age, sensitivity analyses were conducted, 
which yielded similar results of disproportionality. Applying 
a stricter definition of POF (amenorrhea, premature meno-
pause, ovarian failure) or restricting the time period post-
launch of HPV vaccines, the PRRs increased, but as shown 
by very broad 95% CIs, the estimates were very imprecise. 
In relation to sensitivity analysis involving unknown sex, 
even if the 14 POF events were assigned to females and the 
80,119 other events to males, the signal was still present. It is 
worth noting that histological findings on gonad functioning 
of male rats after HPV vaccination was normal in preclini-
cal trials [15], which confirms that the sensitivity analysis 
on unknown sex yielded conservative estimates of the PRR.
Fig. 2  Trend over time of 
reports of POF after market 
launch of the first HPV vaccine. 
POF premature ovarian failure, 
HPV human papilloma virus 
Table 5  Distribution of adverse events in women below 40 years of 
age stratified by POF events and vaccination status between 2 July 
1990 and 14 May 2018 in VAERS
PRR = 46.1 (95% CI: 31.7–67.2)
POF premature ovarian failure, HPV human papillomavirus, AE 
adverse event, VAERS Vaccine Adverse Event Reporting System
a POF events includes cases with unknown age
Adverse events
POF  eventsa Other AEs Total
HPV vaccination 281 38,276 38,557
Other vaccinations 30 189,754 189,784
Total 311 228,030 228,341
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This high PRR estimate, which meets the threshold of a 
lower bound of 95% CI ≥1, and number of reports ≥3 sup-
ports the evidence generated from published case reports 
and case series on the potential association between HPV 
vaccine and POF subsequent to declining menstrual function 
in girls aged between 14 and 21 years [1, 5]. The observed 
increase in POF events reported in the VAERS after the first 
HPV vaccine introduction (2006) should be interpreted with 
caution as the reporting of ADRs is known to be influenced 
by the novelty of the product [16].
There were 281 reports of HPV vaccine and POF events 
following the first approval (in 2006) till 14 May 2018, and 
reports significantly increased among adolescents below 20 
years of age as expected due the indicated age to vaccinate 
against HPV and peak coverages in the female population 
[17–20]. This is consistent with the age of patients reported 
in the published case series [1, 5], with a mean of 16.5 years. 
Using an arbitrary time frame of POF onset date, this study 
showed that almost a third of POF reports with time of onset 
fell within 31 days to 1 year, a period that might be of con-
cern. The majority of reports of POF associated with HPV 
vaccination cited HPV4 as the suspected vaccine type. These 
results were expected as the HPV4 vaccine contributed the 
most doses since approval from June 2006 till present (at 
least 60 million doses distributed in the US compared to 
at least 720,000 doses for HPV2 and at least 28 million for 
HPV 9 distributed in the US) [7]. While published case 
series described cases that received HPV4 vaccines only, 
the current study identified reports of POF events not only 
for HPV4 vaccine but also for HPV2 and HPV9 vaccines, 
even if substantially less. It is important to note that the case 
series referred to were published in 2013 and 2014, respec-
tively, at the time when both HPV2 and HPV4 were already 
on the market [1, 5]. Also, the study showed that among the 
281 reports, POF events were suspected of HPV vaccine 
irrespective of dose rank. Cases where POF occurred fol-
lowing the first, second, or third dose could not be reliably 
derived from VAERS.
The use of amenorrhea as a proxy for POF identification 
is supported by the fact that it is the main initial symptom 
in women with POF [2], which was also the main observed 
POF in our data (i.e., 80.4% of 281 reports). However, only 
few reports referred to ovarian failure (6.4%) and premature 
menopause (15.3%) as well as recorded increased follicle-
stimulating hormone level (5.0%) and decreased estrogen 
hormone level (1.4%). Acknowledging the fact that events 
of declining menstrual function after HPV vaccine are unex-
pected AEs with apparent lack of research in pre- and post-
licensing studies, little or no efforts by clinicians in actual 
practice to follow up patients after vaccination is expected. 
This may lead to incomplete ascertainment of ovarian failure 
and supporting laboratory investigations in the spontane-
ous reports. This under-reporting in the real-world setting 
ties with findings from post-licensing HPV vaccine safety 
studies based on claims data [21] as well as others that were 
not able to recognize them as serious AEs [22, 23]. Thus, 
pharmacoepidemiological studies based on data sources 
including information about vaccination, events, and poten-
tial confounders at patient level are required by using large 
cohorts and a long duration of follow-up.
Following the published case series, the CDC and FDA 
addressed public concerns on POF after HPV vaccination 
Fig. 3  Time to onset for POF 
reports following HPV vaccina-
tion. POF premature ovarian 
failure, AE adverse event, HPV 
human papilloma virus 
*Period of time for which POF is likely not due to vaccination 
POF= Premature ovarian failure 
HPV= Human papilloma virus 
72
41





















Time to onset (days)
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through a VAERS review and a Vaccine Safety Datalink 
study. According to the VAERS review, there were three 
reports among 29 million doses of HPV9 vaccine admin-
istered in the population (1 December 2014–31 Decem-
ber 2017) [7]. All three were determined as unconfirmed 
(lacking sufficient information to confirm a diagnosis 
of POI). Among 17 reports following 60 million HPV4 
vaccine doses (January 2006–2015), two had a physician 
diagnosis of POF, whereas the remaining 15 did not have 
enough information to confirm the diagnosis. Upon fur-
ther causality assessment of physician-diagnosed POFs, 
an association with HPV4 vaccine was deemed unlikely. 
The impact of POF being an unexpected AE may explain 
the dismissal of reports as hearsay. In the Vaccine Safety 
Datalink study, among 199,078 girls aged 9–26 years who 
had been vaccinated with the HPV vaccine, only one con-
firmed case of POF was found, leading to no increased risk 
[4]. The study acknowledged that it was underpowered to 
detect small increases in POI risk associated with vaccina-
tion. Also, apart from absolute measures, estimations of 
the relative risk using as reference unvaccinated patients 
or periods free of vaccination would provide information 
of the association between HPV vaccination and POF.
In the literature, biological plausibility may be possible 
either through toxicity or autoimmune mechanism. Both 
the aluminum- and non-aluminum-containing HPV vac-
cines contain polysorbate 80. One study noted that new-
born rats injected with polysorbate 80 experienced similar 
ovarian damage to those injected with diethylstilbestrol, 
affecting ovaries across all doses tested over a tenfold range 
[24, 25]. Nevertheless, like quantitative signal detection 
methods, the association found in this study may be due to 
chance. Hence, it is required that it is followed up with a 
more robust methodology, which might further investigate 
the effect of polysorbate 80 as an autoimmune hypothesis. 
However, other vaccines contain polysorbate 80, such as 
vaccines against rotavirus, pneumococcal and meningococ-
cal diseases, diphtheria, tetanus, pertussis, influenza, hepa-
titis A and B, and poliomyelitis [26]. It is possible, how-
ever, that they tend to be administered mostly to babies or 
to the elderly, and these people may not be at risk of POF.
This study appears to be the first to quantitatively iden-
tify a potential safety signal of disproportionate reporting 
of POF events following HPV vaccination using a sponta-
neous reporting database (VAERS). VAERS is a national 
database that covers over 300 million inhabitants, supple-
mented by non-US cases that may also be reported. Such 
a large coverage also enables the detection of rare adverse 
events, including POF events. More specific to VAERS 
is the length of coverage, as data are available since its 
inception in 1990, which allows the investigation of safety 
reports of HPV vaccines from the time they were launched 
on the market.
4.1  Study Limitations
Like all spontaneous reporting systems, VAERS is prone 
to reporting bias, which includes the under-reporting of 
AEs, especially for those with delayed onset, such as POF. 
Despite the likely under-reporting, a strong safety signal was 
uncovered in this study. Hence, more cases included may not 
have changed the conclusions. However, differential under-
reporting, i.e., more reporting of POF cases for HPV vaccines 
compared to other vaccines, may have spuriously inflated the 
strength of the signal. Greater reporting of POF cases associ-
ated with HPV vaccines may have been caused by the novelty 
of the vaccine compared to the other vaccines, or by media/
literature coverage, as found for other products [27]. Such an 
increase may have been due to greater scrutiny in the time 
period following marketing of new vaccines, referred to as 
the Weber effect [16], or following the publication of the VSD 
study in 2014 [4]. This is unlikely because the number of 
cases has remained fairly stable in the time period following 
launch, while acknowledging the fact that the increase was 
attributable to non-US cases as trends over time in US cases 
plateaued during this time period. In addition, the sensitivity 
analysis excluding the peak of reports in 2016 still yielded a 
large PRR. Though manufacturers make up greater than 99% 
of non-US reports [10], it is not known how many countries 
have contributed to non-US cases overtime. A Weber effect 
would be associated with an increase immediately after launch 
followed by a decrease over time in the number of reports. The 
increase in the number of reports following the launch of HPV 
vaccines could be due to the characteristics of the target popu-
lation for the HPV vaccines (young women) rather than a vac-
cine effect. In fact, more contact with the healthcare system 
would occur due to the vaccination and therefore increase the 
probability of detecting POF. Concerning non-US reports, a 
greater majority come from manufacturers in compliance with 
an FDA requirement, which may lead to differences in the 
types of events reported and the information provided in the 
reports (information bias) [10]. However, with under-report-
ing of cases being the main concern, reporting by manufactur-
ers is of little concern for this particular study. As of 1 May 
2017 the HPV4 vaccine has no longer been available, leaving 
the HPV9 vaccine as the only vaccine being distributed in the 
USA after its recommendation by the US Advisory Commit-
tee on Immunization Practices in 2014 [28]. With the HPV4 
vaccine, the vaccine type registered in the majority of POF 
reports, no longer in circulation in the market, it is reasonable 
to expect a drop in POF reports after 2016.
There was a variability in the quality and completeness of 
POF case reports, such as absence of information on follicle-
stimulating hormone and estrogen hormone levels in the 
majority of the reports. Incomplete data call into question 
whether or not the identified reports for HPV vaccine and POF 
events are actually valid cases, with POF as the true diagnosis. 
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Finally, VAERS cannot be used to determine whether a vac-
cine caused an AE as it could be due to chance, confounders, 
or bias. Therefore, this study only generated the hypothesis that 
there may be a signal of disproportionate reporting for POF 
events and HPV vaccine that warrants further investigation.
5  Conclusion
This study has detected a strong disproportionality in the report-
ing of POF events after HPV vaccine in VAERS. Besides amen-
orrhea, which is the most frequently mentioned POF event, 
other events such as ovarian failure, premature menopause, 
oligomenorrhea, and blood follicle hormone and estrogen hor-
mone levels were also reported. These findings along with other 
sources of evidence such as the published case series and the 
biological plausibility lend support to the presence of a safety 
signal. The public has been reassured by health authorities of 
the absence of a causal relationship between HPV vaccine and 
POF not only based on safety studies that lacked data on ovar-
ian dysfunction but also on those studies with sources of data 
that were insufficiently powered to detect events of declining 
ovarian function. With an increase in the uptake of HPV vacci-
nation programs in more countries, the population of adolescent 
girls (9–16 years) at risk of potential ovarian dysfunction after 
HPV vaccination is increasing and combined with the signifi-
cant negative consequences on future health and prospects of 
motherhood, this signal warrants well-designed and appropriate 
epidemiological research. If the signal is confirmed, the risk is 
small compared to the lifetime risk of cervical cancer, espe-
cially in developing countries. The population-based benefit-
risk will always be very high. However, on an individual basis, 
the vaccinee needs to be made aware as POF may not be of 
minor importance for everyone, and the benefit-risk of vacci-
nation regarding the risk of POF versus cervical cancer would 
need to be assessed differently in each situation.
Appendix 1‑ Sensitivity analyses
Distribution of adverse events in women aged 
below 40 years with inclusion of unknown sex
Adverse events
POF events Other AEs Total
HPV vaccination 295 48,172 48,467
Other vaccinations 30 259,441 259,471
Total 325 307,613 307,938
PRR = 52.6 (95% CI: 36.2–76.6)
POF premature ovarian failure, AE adverse event, HPV human papil-
loma virus
Distribution of adverse event reports using 
a restricted definition of POF (amenorrhea, 
premature menopause, and ovarian failure)
Adverse events
POF events Other  eventsa Total
HPV vaccination 265 38,292 38,557
Other vaccinations 26 189,758 189,784
Total 291 228,050 228,341
PRR = 50.2 (95% CI: 33.6–75.0)
POF premature ovarian failure, AE adverse event, HPV human papil-
loma virus
a Cases excluded from the stricter POF definition were added to cases 
with other events
Distribution of adverse event reports 
excluding reports of unknown age
Adverse events
POF events Other events Total
HPV vaccination 205 31,588 31,793
Other vaccinations 23 168,991 169,014
Total 228 200,579 200,807
PRR = 47.4 (95% CI: 30.9–72.9)
POF premature ovarian failure, AE adverse event, HPV human papil-
loma virus
Distribution of adverse events in women below 40 
years of age stratified by POF events and other 
events among exposure and non‑exposure to HPV 
vaccination between 1 July 2006 and 14 May 2018
Adverse events
POF events Other AEs Total
HPV vaccination 281 38,276 38,557
Other vaccinations 7 108,139 108,146
Total 288 146,415 146,703
PRR=112.6 (95% CI: 53.4–238.3)
POF premature ovarian failure, AE adverse event, HPV human papil-
loma virus
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